Document is current
Any future updates will be listed below
-
Authors
Romanovsky, Eva https://orcid.org/0000-0002-0059-1977
Menzel, Michael https://orcid.org/0000-0002-4129-4741
Kluck, Klaus https://orcid.org/0009-0001-1000-8052
Beck, Susanne https://orcid.org/0000-0002-2652-8722
Ball, Markus https://orcid.org/0000-0002-2312-8360
Schirmacher, Peter
Kazdal, Daniel https://orcid.org/0000-0001-8187-3281
Stenzinger, Albrecht https://orcid.org/0000-0003-1001-103X
Budczies, Jan https://orcid.org/0000-0002-6668-5327
- License Information
-
More Information
Article History
Received: 4 November 2024
Accepted: 14 July 2025
First Online: 29 July 2025
Competing interests
: P.S. reports personal fees for speaker honoraria BMS, grants from BMS, AstraZeneca, MSD, and boards from BMS, AstraZeneca, MSD, outside the submitted work. D.K. reports personal fees for speaker’s honoraria from AstraZeneca, and Pfizer, personal fees for Advisory Board from Bristol-Myers Squibb, outside the submitted work. A.S. has received advisory boards from Agilent, Aignostics, Amgen, Astellas, Astra Zeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, QuiP, Roche, Sanofi, Seagen, Servier, Takeda, Thermo Fisher, and grants from Bayer, BMS, Chugai, Incyte, MSD, outside the submitted work. J.B. reports grants from German Cancer Aid and consulting from MSD, outside the submitted work. All remaining authors declare that they have no conflict of interest, outside the submitted work.
